IL6 and neoplasm: At the time of the multi-analyte flow assay analysis, the baseline plasma IL-6 concentration significantly differed between patients with the best tumor response as PD and non-PD in the CICAMS cohort, although seven other cytokines were not found to be significantly altered (Fig. 1A).